InMed Pharmaceuticals Inc. received notice from Nasdaq on June 3, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company had previously been notified of non-compliance on March 27, 2026, after its shares closed below $1.00 for 30 consecutive trading days. InMed Pharmaceuticals is a pharmaceutical company that develops and commercializes medical treatments.
